-
1
This study analyzed 82 patients treated with PD-1 inhibitors, identifying 26 who developed hypophysitis and 56 matched controls.
-
2
The hypophysitis group exhibited a higher tumor mutational burden (6.02 vs. 5.19 mut/Mb, P = 0.002) compared to controls.
-
3
Significant mutations in BABAM1, KDM5C, CDH4, and TAL1 were more prevalent in the hypophysitis group, indicating potential genomic associations.
-
4
PAXIP1 mutations were more common in the non-hypophysitis group, suggesting a possible protective role against hypophysitis.
-
5
The findings propose a genomic framework for future studies on endocrine immune-related adverse events in patients receiving PD-1 inhibitors.
